GSK plc reported a 5.7% quarter-on-quarter revenue increase to $11.81 billion in Q3, beating analyst expectations. Key drivers included Cabenuva, its long-acting HIV treatment, which saw sales rise 35.2% year-over-year to $641 million, and Jemperli, a PD-1-blocking antibody, with sales up 10.3% quarter-on-quarter to $365 million. These strong results support maintaining a 'Buy' rating on GSK, alongside its attractive 3.6% dividend yield. The company remains a major player in the HIV therapeutics market and continues to deliver growth through innovative treatments.
As of Oct 28, 2026 22:12 WIB, GSK trades at USD 49.09 on Pluang, down 3.63% for the day despite its strong Q3 revenue growth and a 3.6% dividend yield. The stock shows a market cap of $102.85 billion and an enterprise value of $123.04 billion. Notably, Pluang order activity is currently 100% sell, reflecting cautious sentiment among investors.
